Lataa...
1600. Closing the gap on moxifloxacin breakpoints for Stenotrophomonas maltophilia
BACKGROUND: Moxifloxacin (MOX) has in vitro activity against Enterobacterales and Stenotrophomonas maltophilia (SM). Although MOX commonly displays lower minimum inhibitory concentration (MIC)(50/90) values against SM when compared to levofloxacin, there are currently no established MOX breakpoints...
Tallennettuna:
| Julkaisussa: | Open Forum Infect Dis |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7776320/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1780 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|